MDS Makes Three-Year Commitment to the International Union Against Cancer TORONTO, Feb. 4 /PRNewswire-FirstCall/ -- MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, declared its increased commitment to the fight against cancer today designating it as MDS' major charitable cause. MDS has launched employee awareness and fundraising events around the world and announced a donation of nearly $1 million over the next three years to the International Union Against Cancer (UICC). MDS chose UICC, the world's largest non-governmental association of cancer-fighting organizations, because of its global mission to fight the disease. With the support of partners like MDS, UICC acts as a resource for action and a voice for change through prevention education programs, research projects, and other initiatives that can make a real difference in saving lives and improving the quality of life for cancer patients and their families throughout the world. "We are thrilled to support the work of the International Union Against Cancer," said Stephen P. DeFalco, President and Chief Executive Officer of MDS Inc. "We have great employees at MDS who are committed to this fight both as a company and as individuals, not only on World Cancer Day but every day they come to work." Each year, more than 11 million new cases of cancer are diagnosed and more than 7 million people die from cancer. Through its life sciences businesses, MDS wages a fight against cancer every day: - MDS has identified oncology as a focus area of clinical research activity and conducts cancer studies around the world as part of its full set of contract research services. - MDS partners with pharma and biotech customers using its isotope technologies to develop new radiotherapeutics to treat cancers like non-Hodgkin's lymphoma and primary liver cancer. - MDS produces instruments and reagents researchers use to understand the disease mechanisms and develop new drug therapies. About MDS MDS is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a day. Source data: International Union Against Cancer http://www.uicc.org/ DATASOURCE: MDS Inc. CONTACT: Sharon Mathers, Senior Vice-President, Investor Relations and External Communications, MDS Inc., (416) 675-6777 x34721,

Copyright